
Novo Nordisk Signs $1.4B Deal with Orbis Medicines for Oral Cardiometabolic Drugs
Novo Nordisk has agreed to a collaboration with Copenhagen-based biotech Orbis Medicines, involving total payments of up to $1.4 billion. The partnership focuses on developing orally bioavailable macrocycle therapies for cardiometabolic diseases, aiming to replace injectable treatments. This deal represents Orbis's first major pharma partnership and comes as Novo seeks to diversify its pipeline following recent setbacks in its GLP-1 and inflammation drug programs.


